INTRODUCTION
============

Tuberculosis (TB) is an infectious disease caused by *Mycobacterium tuberculosis* (MBT) and rarely by *Mycobacterium bovis* that mainly involves the lungs. Although effective treatment regimens are being used widely, TB is one of the most important problems worldwide with an incidence of 12 million cases in 2011 \[[@b1-phrp-08-003]--[@b4-phrp-08-003]\]. The incidence of all TB cases and smear-positive cases in Iran during 2012 were reportedly 13.7 and 6.4 per 100,000 population, respectively \[[@b5-phrp-08-003],[@b6-phrp-08-003]\].

Children play a key role in the epidemiology and transmission of TB infection. They can become infected after exposure to smear-positive cases and develop active TB during their lives following any immune system impairment, malnutrition, stress, hormonal changes (especially in women), pregnancy, and elderly. Therefore, age group is of great importance in the TB control programs as a potential reservoir for MBT \[[@b7-phrp-08-003],[@b8-phrp-08-003]\]. Bacillus Calmette-Guérin (BCG) vaccination is a simple method of providing a high degree of immune protection to those without a previous MBT infection. The BCG vaccine first used in 1928 should be prescribed in countries with high TB prevalence. This vaccine has been used in Iran since 1989 \[[@b1-phrp-08-003],[@b9-phrp-08-003],[@b10-phrp-08-003]\].

The prophylactic effect of the BCG vaccine is under debate; however, since it prevents the disseminated and dangerous forms of TB disease and no other immune vaccines have been developed, the BCG vaccine is widely used worldwide \[[@b11-phrp-08-003]\]. In addition, although BCG is a safe vaccine, some adverse reactions such as cellulitis, abscess development at the injection site, regional lymphadenitis, and disseminated BCG infection have been reported \[[@b12-phrp-08-003]\].

The tuberculin test, the most common method of BCG vaccination evaluation, is used as a diagnostic parameter for TB infection. The reports of average reaction sizes vary among countries. For example, the frequencies of a positive purified protein derivative (PPD) reaction in Ugandan adolescents, Indian children \< 5 years of age, 11--18-year-old teenagers in South India, and Gambian school children were reportedly 16% \[[@b13-phrp-08-003]\], 20% \[[@b14-phrp-08-003]\], 12% \[[@b15-phrp-08-003]\], and 6.9% \[[@b16-phrp-08-003]\], respectively.

Several primary studies have been performed in Iran to estimate the frequencies of positive PPD reactions among different age groups. Combining the various results of these studies using systematic review and meta-analytic methods \[[@b17-phrp-08-003]--[@b19-phrp-08-003]\] can provide more reliable evidence. Therefore, we aimed to estimate the pooled prevalence of positive PPD reactions in Iranian children and adolescents who received a BCG vaccination at birth.

MATERIALS AND METHODS
=====================

1. Search strategy
------------------

All national (SID, Magiran, and Medlib) and international (PubMed, Google Scholar, Scopus, and Science Direct) databanks were electronically searched to identify relevant studies published between 1995 and January 31, 2016 using the following keywords and their Farsi equivalents: "prevalence," "frequency," "percent," "latent tuberculosis infection," "tuberculin skin test," "TST," "LTBI," "LTI," "purified protein derivative," "PPD," "tuberculin test," "latent tuberculosis," "cross-sectional study," "descriptive study," "longitudinal study," "cohort study," "Iran," and "children."

Two researchers independently performed the search during February 2 to 18, 2016. They also investigated all references of the identified studies to increase the search sensitivity. Another researcher randomly evaluated the search results to identify any previously ignored study. To find unpublished materials, non-electronic evidence was also searched. Moreover, we interviewed relevant experts and research centers to identify any available grey literature.

2. Study selection
------------------

Full texts or abstracts of all documents found during the primary search were obtained. Duplicate and irrelevant papers were excluded after investigation of the titles, abstracts, and full texts. We also investigated the results to identify and remove all duplicate studies.

3. Quality assessment
---------------------

All selected papers were quality assessed using a pre-designed checklist used in previous studies \[[@b20-phrp-08-003]\]. This checklist was designed based on the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist \[[@b21-phrp-08-003]\] and included 12 questions regarding different aspects of the methodology such as study type, sample size and sampling design, study population, data collection method and instruments, variable definition, statistical tests, study objectives, and illustration of the results based on the objectives. One score was assigned to each question and studies with at least eight scores \[[@b20-phrp-08-003]\] were entered into the final meta-analysis.

4. Data extraction
------------------

Required data were extracted from the studies including title, first author name, study date and location, study type, sample size and sampling methods, average sample age and range, publication language, cut-off point of the PPD reaction size for latent TB infection, skin test measurement date, BCG vaccination status, exposure to active TB cases, study sample source (hospital or community), frequency of samples with different PPD reaction sizes (0--5, 6--9, or ≥ 10 mm). Extracted data were entered into an Excel spreadsheet (Microsoft, Redmond, WA, USA).

5. Inclusion criteria
---------------------

All Persian and English written papers with sufficient quality scores and reporting sample size and tuberculin skin test results among an Iranian population of patients \< 18 years of age were included in the meta-analysis.

6. Exclusion criteria
---------------------

Studies did not report tuberculin skin test reactions, BCG vaccination status and sample size, those conducted among TB suspicious populations or TB-exposed populations and \> 18-year-old populations, full text free abstracts presented in congresses, case reports, case control and experimental studies, and studies that did not obtain high enough quality scores were excluded from the meta-analysis.

7. Statistical analysis
-----------------------

The data analyses were performed using Stata ver. 11 software (Stata Corporation, College Station, TX, USA). The standard error of the MBT infection prevalence was calculated using the binomial distribution formula. The Cochrane (Q) test and I^2^ index were used to determine the degree of heterogeneity among the results of the primary studies. Based on the heterogeneity indices, a random effects model was used to combine the point estimates. Factors that influenced the heterogeneity were investigated using meta-regression models. We also analyzed the results in the different subgroups such as publication date, study group, and publication language. Point prevalences of MBT infection were illustrated in a forest plot. In this graph, each box represents the weight of the study and the cross-lines indicate the 95% confidence intervals (CIs). Since this meta-analysis was used to estimate a single indicator, publication bias was not assessed.

RESULTS
=======

The 9,643 studies initially identified were reduced to 463 after restriction of the search strategy. Moreover, 167 duplicates were removed. During the title/abstract review, 211 irrelevant studies were excluded. The full-text review revealed 71 irrelevant papers. One relevant study was identified during the backwards citation tracking process. Another paper did not achieve required quality score. Ultimately, 14 articles were identified as being eligible for the meta-analysis ([Figure 1](#f1-phrp-08-003){ref-type="fig"}).

The frequency of a positive PPD reaction was investigated among 26,281 Iranian children and adolescents. These studies were published from 1995 by Nilforooshan (17% prevalence of TB infection) to 2015 by Masomi Asl (3.8% prevalence of TB infection) and Raffiee (14.1% prevalence of TB infection) ([Table 1](#t1-phrp-08-003){ref-type="table"}). Healthy vaccinated children unexposed to active TB cases were recruited in all studies. Tuberculin test results were measured 48--72 hours after injection. All studies used five units of tuberculin (0.1 mL forearm intradermal injection).

Minimum and maximum positive reactions (\> 10 mm) in the primary studies varied from zero in the study by Sakha in 2008 among children aged 84--96 months to 26.3% in the study by Zehni in 2001 among children aged 132--168 months ([Table 1](#t1-phrp-08-003){ref-type="table"}).

As illustrated in [Figure 2](#f2-phrp-08-003){ref-type="fig"}, based on the random effects model, the prevalence of a positive reaction (\> 10 mm) among Iranian children and adolescents was estimated to be 8.5% (95% CI, 6.2--10.8; I^2^, 98.4%; Q, 822.20; *p* \< 0.001).

Due to the considerable heterogeneity among the results of the primary studies, meta-regression model investigation of the "year of publication" variable showed a significant influence on heterogeneity (β = −0.8, *p* = 0.009) ([Figure 3](#f3-phrp-08-003){ref-type="fig"}).

The prevalence of positive reactions in the six studies conducted before 2008 was estimated to be 12.5% (95% CI, 5.6--19.5), while the prevalence in the eight studies performed after 2008 was estimated to be 5.8% (95% CI, 4.1--7.5). In addition, the frequency of positive reactions (≥ 10 mm) among children \< 6 years of age was 10.7% (95% CI, 4.4--17), among children aged 6--16 years of age was 8.89% (95% CI, 5.3--12.7), and among those aged 3 months to 16 years was 5.5% (95% CI, 3.4--7.6). The observed overlaps between the confidence intervals for the different age groups indicated that these differences were not statistically significant ([Figure 4](#f4-phrp-08-003){ref-type="fig"}).

The prevalence of 5--9-mm skin reaction sizes among Iranian children was estimated to be 29.9% (95% CI, 22.3--37.4), while that for reactions sizes \< 5 mm was 59.99% (95% CI, 48.9--71.1) ([Figures 5](#f5-phrp-08-003){ref-type="fig"} and [6](#f6-phrp-08-003){ref-type="fig"}).

DISCUSSION
==========

Our meta-analysis showed that 8.5% of Iranian children and teenagers with a history of BCG vaccination during the first 3 months of life had PPD skin reaction sizes ≥ 10 mm. Moreover, we found that about 60% of them showed no test reaction. Reaction sizes \> 10 mm were more common in the recent than older studies.

During a meta-analysis conducted in 2002 \[[@b22-phrp-08-003]\], the prevalence of a PPD reaction size \> 10 mm was estimated to be 22.8% when combining the tuberculin skin test results in the USA, Canada, Queensland, and Spain. The corresponding rate for the survey results in the Philippines, Saudi Arabia, Solomon Island, South America, Turkey, and United Arab Emirates was 28.8%. These results are considerably higher than those estimated in the current study. One explanation for such variations is differences in the study samples. In these meta-analyses, the time gap between BCG vaccination and tuberculin testing was at least 5 years, while our study samples received the BCG vaccine at least 3 months prior to PPD testing. It seems that the greater the time interval between immunization and PPD testing, the greater the PPD reaction sizes would be observed. Wang et al \[[@b22-phrp-08-003]\] combined the results of different studies by time interval and estimated the prevalence of positive PPD skin test results for populations whose time gaps were \< 15 years as of 12.6%, while the corresponding prevalence for those with a time gap \> 15 years was estimated to be 47.2%. Age differences among populations can be another reason for such variations. The mean age in the Wang et al's study populations was more than that in the current meta-analysis. In addition, the dates of tuberculin surveys are different in our study (1995--2015) from those in the study performed by Wang et al (1996--1999). Moreover, the prevalences of TB, malnutrition, HIV/AIDS, and other immunocompromised disorders differed among studies.

The prevalence of positive tuberculin skin test reactions has been reported in many studies in different parts of the world, such as 16.1% in Ugandan adolescents \[[@b15-phrp-08-003]\], 20% in Indian children \< 5 years of age \[[@b14-phrp-08-003]\], 12% among 11--18-year-old teenagers in southern India \[[@b14-phrp-08-003]\], and 6.9% in Gambian school children \[[@b16-phrp-08-003]\]. The reported prevalences in three studies \[[@b13-phrp-08-003]--[@b15-phrp-08-003]\] were higher than those of the current Iranian meta-analysis. Only the Gambian survey \[[@b16-phrp-08-003]\] showed lower estimates than Iran. Another survey of Chinese children \> 5 years of age \[[@b23-phrp-08-003]\] reported an age-sex standardized prevalence of positive PPD tests of 15% to 42%, which was higher than our estimates.

Marquez et al \[[@b24-phrp-08-003]\] reported a 24% prevalence of positive PPD tests among Ugandan children \< 5 years of age. It was at most 36% among children in the first year of life and at least 19% in children aged 36--60 months. Both estimates are higher than ours. The higher prevalence of HIV/AIDS might explain such differences. Another study performed in southeast Iran showed significant differences in reaction sizes between the sexes but no difference among age groups \[[@b25-phrp-08-003]\].

Many factors influence the tuberculin skin test reaction sizes including vaccine type and dose, vaccination age and time, history of MBT exposure, history of active TB exposure, time interval between BCG vaccination and PPD testing, children's nutritional status, and PPD booster effect \[[@b26-phrp-08-003]--[@b28-phrp-08-003]\]. All of these factors can be reasons for the observed heterogeneity among the results of different tuberculin skin test surveys.

Some of our TB-infected study samples might be due to exposure to untreated TB. Most of the samples showed no PPD reaction. Because of remarkable delays in TB diagnosis in Iran, these non-response groups are susceptible to developing TB. According to several studies conducted in Iran, there are notable delays in both diagnosis and treatment of TB patients. Alavi et al \[[@b29-phrp-08-003]\] showed that 65.5% of smear-positive TB cases in Khuzestan province started TB treatment after an average delay of 73 days. Another cross-sectional study in Iran reported a 59-day delay \[[@b30-phrp-08-003]\]. Since the low efficacy of BCG vaccination in TB prevention, such a delay can be an important potential source of new infections among children. Another study performed in Russia reported an increasing trend for TB infection from 0.2% in 1991 to 1.6% in 2000 \[[@b31-phrp-08-003]\].

One of the limitations of the current study was its wide age range among the study populations, which could be a probable factor for unreliable results. In four studies, the sample age was 3--16 months made it difficult to analyze the results according to \< 6-year-old and \> 6-year-old age groups. The significant heterogeneity between the results of primary studies was another limitation of our meta-analysis. Therefore, we applied the random effects model to combine the results. We also did not report the pooled results based on sex because such sub-analyses had not been reported in the primary studies. However, using the cut-off point method as an indicator of TB infection prevalence is prone to challenges, and more reliable methods for interpreting PPD skin reactions were applied in some of the primary studies that reported different results \[[@b32-phrp-08-003]\].

Our study revealed that a major proportion of Iranian children and adolescents had no positive reaction after BCG vaccination, whereas some had latent TB infection. Results of this study showed an acceptable view of BCG efficacy and latent TB infection among these age groups. Note that early case detection and treatment is the most effective strategy for controlling TB infection and disease and that reinforcement of case finding and control programs can help achieving these strategies. Future similar studies among limited age ranges of populations are needed to confirm our results.
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![Investigating "publication year" as a heterogeneity factor on meta-regression analysis.\
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ES, effect size; CI, confidence interval.](phrp-08-003f5){#f5-phrp-08-003}
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###### 

Characteristics of primary studies included in the meta-analysis

  First author        Publication year   Local study              Language publication   Age group      Sample size (n)   PPD (%)           
  ------------------- ------------------ ------------------------ ---------------------- -------------- ----------------- --------- ------- -------
  Nilforooshan        1995               Tehran                   Persian                \< 6 y         200               32.0      51.0    17.0
  Daie Parizi         2000               Kerman                   Persian                3 mo to 18 y   247               31.6      55.9    12.5
  Mahyar              2000               Markazi                  Persian                \< 6 y         612               39.9      42      18.1
  Masoumi Asl         2012               Fars                     Persian                3 mo to 18 y   1,289             76.1      19.4    4.5
  Sedighi             2013               Hamedan                  Persian                \< 6 y         564               --        --      3.0
  Zehni               2001               Kurdistan                Persian                6--18 y        1,381             51.2      22.5    26.3
  Alavi               2008               Khuzestan                English                6--18 y        3,906             91.7      6.1     2.2
  Haghdoost           2014               Sistan and Baluchestan   English                6--18 y        5,390             91.5      3.8     4.7
  Hemmati             2011               Kermanshah               English                6--18 y        10,184            --        --      8.2
  Masoumi Asl         2015               Fars                     English                3 mo to 18 y   967               77.5      18.7    3.8
  Sayyahfar           2014               Tehran                   English                3 mo to 18 y   236               --        --      4.7
  Raffiee             2015               Kermanshah               English                6--18 y        361               32.14     53.73   14.13
  Rafiei Tabatabaei   2013               Arak                     English                \< 6 y         794               39.0      55.0    6.0
  Sakha               2008               Tabriz                   English                6--18 y        150               95.3      4.7     0

PPD, purified protein derivative.
